Anzupgo

For the treatment of moderate-to-severe chronic hand eczema (CHE) in adults when all of the following apply:

1. the patient is 18 years of age or older; AND
2. the patient has moderate-to-severe CHE as defined by a Physician Global Assessment (PGA) or Investigator Global Assessment of CHE (IGA-CHE) score of 3 to 4; AND
3. the patient’s PGA or IGA-CHE score of 3 to 4 is obtained after an 8-week course of high-potency topical corticosteroids, or the patient has documented intolerance to high-potency topical corticosteroids, or the patient is ineligible to receive high-potency topical corticosteroids.

Response should be assessed at 12 weeks.

Renewal: For continuation of reimbursement, the patient must demonstrate at least a 2-step improvement of IGA-CHE or PGA score, or a score of 0 to 1 (clear/almost clear) at the 12-week assessment.

Of note, treatment should be discontinued when signs and symptoms of CHE resolve. In the event of recurrence of the signs and symptoms of CHE, treatment of the affected areas should be re-initiated as needed.